Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial - Burnett, A K; Russell, N H; Hills, R K; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group (Lancet Oncol, 2015)